Averting radiation damage
Updated: Nov 5, 2019
Up to half of the patients who receive radiotherapy will suffer unwanted organ or tissue damage from ionising radiation, and up to 1% will develop secondary tumours as a result. Minimising the risks of this collateral damage is the focus of a new technology called MOSkin developed at the University of Wollongong (UOW).
Up to half of the patients who receive radiotherapy will suffer unwanted organ or tissue
MOSkin is a cost-effective next-generation medical radiation dosimeter/sensor for the precise, real-time measurement of the depth and intensity of ionising radiation. It is well-positioned to be a major disruptive technology in a wide range of multi-billion dollar medical applications including radiotherapy, angiography and diagnostic/interventional scans. The technology forms a key part of quality assurance allowing greater real-time control of the amount of radiation delivered, leading to better outcomes for patients by reducing the incidence of under or over-delivery of radiation.
Proven in clinical tests in Australia, Italy, Brazil and Malaysia over the last 8 years MOSkin is now ready for commercialisation by Electrogenics Laboratories. MOSkin will be the focus of a MedTech Hypothetical event run by the NSW Active MedTech Community.
The CEO of Electrogenics, Kim Lyle, will present the case and leading service providers will suggest what the critical success factors for the product are, in an open interactive session at the Venture Café Sydney.
Electrogenics will develop a full sensor product range for multiple medical applications and optimise large-scale production processes for the devices. The aim is to establish MOSkin sensors the global industry standard for radiation dose monitoring in real-time. The ideal outcome is rapid adoption resulting in improved long-term patient health and survival rates.
The technology was invented by Professor Anatoly Rozenfeld at the Centre for Medical Radiation Physics at UOW.